Bio-preservation Technology Recognized … by most clinical trial-stage cellular therapies
BLFS' novel bio-preservation technology is being used in more than 50 clinical trial-stage cellular therapies, making it the leading choice in the emerging, high growth field of regenerative medicine.
BLFS holds the number #1 supplier position among companies offering pre-formulated cell and tissue storage and freeze media used in clinical trial stage cellular therapies to treat the leading causes of death and disability such as cancer, heart disease, stroke, and joint/movement disorders.
The Bottom Line: Cutting to the point - "When you are providing <critical reagents>, it is always better to integrate cumulative positive and negative yield … and cost impact .. in reference to … cryopreservation freeze media for cells and tissues, and contract aseptic media … "home brewing" is not the way to go". BLFS' revenue from its growing RegMed customer base, along with its selective targeting of contract manufacturing customers, should positive generate cash and profits as adaption continues and clients gain approvals. At that point, profitable growth should accelerate in a step-wise fashion. Recognition by … more companies and hospital-based transplant centers using pre-formulated storage, shipping, and freeze media products has come as BLFS has consistently converted these customers … from using 'home-brew' formulations to our cGMP, protein-free, serum-free biopreservation media products.Product shelf life and post-preservation viability are critical to good clinical outcomes and commercial success, enabling the reduction in overall manufacturing costs … through the use of BLFS products as HypoThermosol and CryoStor are recognized as critical reagents.
Markets are closed today <Monday>, as a major hurricane swamps the eastern seaboard. BLFS closed on Friday, 10/26 at $0.27 up $0.01 or +3.85%. Excerpting, from Friday's mid-day … I continue to reiterate BLFS as a BUY … as BLFS "HIT" my short-term hurdle in a very down dropping market …to $0.33 with a minor retreat and … as I "had" said … $0.30 for 11/15! Looking to the future <1-2 months or years end> … a $0.50 target would still be a very modest prognostication!
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.